Relay Therapeutics, Inc. (RLAY) - 10-Q Summary
Business Context and Reporting Period
Company: Relay Therapeutics, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Relay is a clinical-stage precision medicine company utilizing its Dynamo® platform to develop small molecule therapies for cancer and genetic diseases. The company has no products approved for commercial sale and has not generated revenue from product sales. Its lead product candidate, zovegalisib (RLY-2608), is in Phase 3 development for breast cancer and Phase 1/2 for vascular anomalies. The company also has an NRAS-selective inhibitor (RLY-8161) in clinical trials.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|
| Total Revenue | $350 | $3,350 | $8,355 |
| Net Loss | $(83,707) | $(156,998) | $(147,440) |
| Net Loss Per Share (Basic & Diluted) | $(0.41) | $(0.82) | $(0.87) |
| Research & Development Expenses | $76,483 | $147,046 | $137,706 |
| General & Administrative Expenses | $14,691 | $25,718 | $32,366 |
| Cash, Cash Equivalents & Investments | $910,934 (as of June 30, 2026) | ||
| Accumulated Deficit | $(2,171,767) (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue for the six months ended June 30, 2026, decreased by $5.0 million (60%) compared to the same period in 2025. This was primarily due to the recognition of milestone payments and performance obligations under the Elevar Therapeutics license agreement in the prior year, which were not repeated in the current period.
- Increased R&D Spend: R&D expenses increased by $9.3 million (7%) year-over-year for the six-month period. This increase was driven by higher external costs for programs in clinical trials, specifically for zovegalisib, partially offset by strategic streamlining of the research organization.
- Decreased G&A Spend: G&A expenses decreased by $6.6 million (21%) year-over-year, primarily due to lower employee compensation costs (including stock compensation) and the absence of costs to obtain the Elevar Agreement which were expensed in the prior year.
- Capital Raising: The company significantly increased its liquidity position through equity financing. In May 2026, it completed a follow-on offering raising $296.8 million (net). Additionally, it raised $159.2 million (net) via at-the-market offerings during the six-month period.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes that existing cash, cash equivalents, and investments of approximately $911 million as of June 30, 2026, will fund operating expenses and capital expenditures into 2029.
- Clinical Progress:
- Zovegalisib: Received FDA Breakthrough Therapy Designation in February 2026 for combination therapy in breast cancer. The Phase 3 ReDiscover-2 trial is ongoing. Interim data from the ReDiscover trial and triplet combination arms (with atirmociclib) were announced in 2026 showing encouraging safety and efficacy signals.
- RLY-8161: Clinical trial initiated for NRAS-mutant melanoma and solid tumors.
- Key Risks:
- Regulatory & Clinical: No products approved; clinical trials may fail or be delayed. Positive early data is not predictive of later-stage success.
- Supply Chain (BIOSECURE Act): The company relies on third-party manufacturers, including WuXi AppTec in China. The U.S. BIOSECURE Act (Section 851 of the NDAA 2026) may restrict U.S. government funding and procurement involving "biotechnology companies of concern," potentially forcing costly and time-consuming supply chain transitions.
- Intellectual Property: Reliance on joint ownership with D.E. Shaw Research for certain platform technologies and potential challenges to patent validity.
- Legal Proceedings: A derivative lawsuit filed in December 2024 regarding alleged excessive director compensation is ongoing in discovery.
Investor Verification Checklist
- Cash Runway: Verify the $911 million cash position and the assumption that it funds operations into 2029, considering the high burn rate (~$157M net loss in H1 2026).
- Supply Chain Exposure: Assess the specific impact of the BIOSECURE Act on the company's reliance on WuXi AppTec and the feasibility/cost of transitioning to alternative manufacturers.
- Clinical Trial Data: Review the full interim data releases for zovegalisib (ReDiscover and ReInspire trials) to validate the "encouraging" efficacy signals cited by management.
- Revenue Sustainability: Confirm the timeline for future milestone payments from the Elevar Therapeutics agreement, as current revenue is minimal and non-recurring.
- Legal Status: Monitor the status of the Hayes v. Borisy derivative lawsuit and any potential financial or governance implications.